Branch Retinal Vein Occlusion Clinical Trials 2023

Branch Retinal Vein Occlusion Clinical Trials 2023

Branch Retinal Vein Occlusion research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in branch retinal vein occlusion clinical trials today.

Popular filter options for branch retinal vein occlusion trials

RVO Clinical Trials

View 9 RVO medical studies.

Macular Edema Clinical Trials

View 6 Macular Edema medical studies.

Branch Retinal Vein Occlusion Clinical Trials With No Placebo

View 15 branch retinal vein occlusion medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to branch retinal vein occlusion

What are the top hospitals conducting branch retinal vein occlusion research?

When it comes to cutting-edge clinical trials in the field of branch retinal vein occlusion, several hospitals stand out for their dedication to advancing treatment options in this condition. The Center for Retina and Macular Disease in Winter Haven leads the way with two active trials focused specifically on branch retinal vein occlusion, building upon their four previous studies conducted since their first trial in 2013. In Toronto, Canada, the Department of Ophthalmology at St Michael's Hospital is making significant contributions as well, currently running two active trials while having completed two earlier investigations since embarking on their research journey in 2017.

Meanwhile, at Retina Consultants of Orange County in Fullerton, California, researchers are conducting one ongoing clinical trial for branch retinal vein occlusion alongside a noteworthy track record of four previously concluded studies after initiating their first trial dedicated to this condition just three years ago. Additionally contributing to the advancement of knowledge and treatments for branch retinal vein occlusion is Mountain View | Ophthalmology based in Loma Linda where one active clinical trial is underway following from its initiation back again only from2023.

Similarly joining the pursuit towards improving outcomes related to branch retinal vein occlusion is South Coast Retina Center located Long Beach; like Mountain View | Ophthalmology they also have an ongoing investigation along with successful completion of another research during early twenty-third century thereby adding value by consistently broadening our understanding about such ailment which affects visual system severely

These hospitals' commitment to conducting clinical trials not only highlights the importance placed on finding new approaches and therapies but signifies a united effort among healthcare professionals worldwide toward better managing and treating patients affected by this vision-threatening condition

Which are the best cities for branch retinal vein occlusion clinical trials?

When it comes to branch retinal vein occlusion (BRVO) clinical trials, several cities are at the forefront of research and innovation. Hagerstown, Maryland stands out with 4 active trials exploring treatments such as Higher Dose Regimen 1, 2 mg ANXV - active, and bevacizumab. Baltimore, Maryland closely follows with 3 ongoing studies focusing on controls and Higher Dose Regimen 1. Philadelphia, Pennsylvania, Maryland stands out with 4 active trials exploring treatments such as Higher Dose Regimen 1, 2 mg ANXV - active, and bevacizumab. Baltimore, Maryland closely follows with 3 ongoing studies focusing on controls and Higher Dose Regimen 1. Philadelphia, Pennsylvania also offers promising opportunities with 3 active trials investigating Higher Dose Regimen 1 and dexamethasone intravitreal implant. San Antonio, Texas contributes to the advancements in BRVO treatment through its involvement in three trials examining Higher Dose Regimen 1 and ANXV - active. Lastly, Toronto, Ontario joins the ranks with its three studies involving AMD/RVO/DME and other potential interventions for BRVO patients. These cities provide individuals affected by BRVO access to cutting-edge clinical trials that may lead to enhanced care options for this condition.

Which are the top treatments for branch retinal vein occlusion being explored in clinical trials?

Ongoing clinical trials exploring treatments for branch retinal vein occlusion have identified aflibercept as a potential game-changer. This powerful drug is currently being tested in one active trial specifically targeting this condition. Since its first listing in 2012, it has already been involved in nine all-time branch retinal vein occlusion trials. With the focus squarely on aflibercept, researchers are hopeful that it will offer new avenues of treatment and improved outcomes for patients grappling with this challenging eye disorder.

What are the most recent clinical trials for branch retinal vein occlusion?

Exciting advancements are being made in the field of branch retinal vein occlusion treatment, with recent clinical trials offering hope for patients. One such trial focuses on a higher dose regimen for the condition, aiming to assess its effectiveness through a Phase 3 study that became available on 5/15/2023. Additionally, a Phase 2 trial involving an active form of ANXV has shown promising results and became available on 8/24/2022. Another notable study explores the use of bevacizumab and aflibercept in separate Phase 3 and Phase 4 trials respectively, providing valuable insights into their potential benefits for branch retinal vein occlusion patients. Furthermore, an early-stage trial investigating episcleral celecoxib is underway since March 2021 to evaluate its safety and tolerability profile. These ongoing research endeavors signify progress towards more effective treatments for those affected by this condition

What branch retinal vein occlusion clinical trials were recently completed?

Recently, several clinical trials investigating treatments for branch retinal vein occlusion have reached significant milestones, bringing hope to individuals affected by this condition. In March 2021, two separate trials sponsored by Hoffmann-La Roche successfully completed their investigations into the effectiveness of Faricimab. Additionally, in December 2020 and September 2020 respectively, Novartis Pharmaceuticals concluded a trial for MHU650 and Kodiak Sciences Inc wrapped up a trial for KSI-301. While not recent but worth mentioning is a trial sponsored by the National Eye Institute (NEI) that explored Minocycline's potential efficacy in treating branch retinal vein occlusion and was completed back in March 2012. These advancements underscore ongoing efforts to find new therapies and enhance patient outcomes within this challenging field of ophthalmology research.